6 million), compared with Rs 236 crore a calendar year earlier. GlaxoSmithKline, which derives almost all of its profits from India, continued to grapple with issues adhering to the inclusion of its important products like Ceftum antibiotic and T-Bact ointment within the place’s National List of Necessary Medicines (NLEM) in September 2022, manda